The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1658
September 5, 2022
View Complete Issue         Table of Contents 2019 
Baricitinib (Olumiant) for Severe Alopecia Areata
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Baricitinib (Olumiant) for Severe Alopecia Areata
September 5, 2022 (Issue: 1658)
The oral Janus kinase (JAK) inhibitor baricitinib (Olumiant – Lilly), which was previously approved by the FDA for treatment of moderately to severely active rheumatoid arthritis and treatment of COVID-19 in certain hospitalized adults, has now...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Baricitinib (Olumiant) for Severe Alopecia Areata
Article code: 1658b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.